Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2747
Abstract: Studies have shown that the prevalence of RAS and BRAF mutations may differ by tumor sidedness among metastatic colorectal cancer (mCRC) patients. Both mutation status and tumor sidedness may impact survival and disease progression and… read more here.
Keywords: tumor sidedness; sided tumors; prevalence ras; prevalence ... See more keywords
Imaging predictors of BRAF mutation in colorectal cancer
Sign Up to like & getrecommendations! Published in 2020 at "Abdominal Radiology"
DOI: 10.1007/s00261-020-02484-9
Abstract: Background Colorectal cancer (CRC) is one of the leading causes of cancer deaths and is associated with various genetic mutations. BRAF mutations, found in approximately 10% of all CRCs, are associated with negative predictive outcomes.… read more here.
Keywords: colorectal cancer; imaging predictors; braf mutation; cancer ... See more keywords
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Sign Up to like & getrecommendations! Published in 2020 at "Targeted Oncology"
DOI: 10.1007/s11523-020-00753-7
Abstract: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug targets. With… read more here.
Keywords: kras nras; cetuximab; nras braf; cancer ... See more keywords
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Sign Up to like & getrecommendations! Published in 2018 at "Oncogene"
DOI: 10.1038/s41388-018-0171-x
Abstract: The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated pathways in human cancer. Approximately 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase. FDA-approved combination therapies of BRAF… read more here.
Keywords: braf alterations; braf; cancer; non v600 ... See more keywords
No Tissue Expression of KRAS or BRAF Mutations in 61 Adult Patients Treated for Esophageal Atresia in Early Childhood
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Pediatric Surgery"
DOI: 10.1055/s-0037-1605346
Abstract: Background Previous studies have reported an association among esophageal atresia (EA), Barrett's esophagus, and esophageal adenocarcinoma later in life. Objective The objective of the article is to evaluate KRAS and BRAF mutations as potential genetic… read more here.
Keywords: kras braf; expression kras; tissue expression; braf mutations ... See more keywords
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Sign Up to like & getrecommendations! Published in 2017 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000398
Abstract: BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAFV600E-mutated melanoma. The results of a descriptive study evaluating vemurafenib… read more here.
Keywords: melanoma; mutations v600e; braf; braf mutations ... See more keywords
Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience
Sign Up to like & getrecommendations! Published in 2022 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000854
Abstract: The widespread use of more sensitive detection tools, such as next-generation sequencing, has increased the identification of a variety of BRAF mutations other than V600E/K in melanoma patients. However, there is a lack of established… read more here.
Keywords: melanoma; braf; melanoma patients; braf mutations ... See more keywords
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high‐grade gastroenteropancreatic neuroendocrine neoplasms
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.13256
Abstract: High‐grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP‐NEN) typically disseminate early. Treatment of metastatic disease has limited benefit and prognosis is generally discouraging. Data on the clinical impact of mutations in HG GEP‐NEN are scarce. There is… read more here.
Keywords: kras braf; colon nec; impact; first line ... See more keywords
A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population
Sign Up to like & getrecommendations! Published in 2022 at "BioMed Research International"
DOI: 10.1155/2022/5824183
Abstract: Globally, colorectal carcinoma (CRC) is the third most common cancer and the third major cause of cancer-related death in both sexes. KRAS and BRAF mutations are almost mutually exclusively involved in the pathogenesis of CRC.… read more here.
Keywords: meta analysis; prevalence; analysis; braf mutations ... See more keywords
BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/0008-5472.can-21-3377
Abstract: Cancer treatment is increasingly guided by molecular analyses designed to identify clinically actionable genomic alterations in individual patients. The discovery of BRAF mutations in human cancer, and the subsequent development and FDA authorization of selective… read more here.
Keywords: lineage specific; specific differences; cancer; braf mutations ... See more keywords
KRAS, NRAS and BRAF Mutations Are Highly Enriched in TRI12 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-111864
Abstract: Background Extensive sequencing data highlighted the recurrence of mutations resulting in constitutive MAP kinase signaling in chronic lymphocytic leukemia (CLL), and proposed these mutations as late drivers of CLL progression (X.S. Puente, Nature, 2015; D.A.… read more here.
Keywords: cll; tri12; kras nras; group ... See more keywords